Introduction and outline 17 CHAPTER 1 17. Bosman SJ, Holman FA, Nieuwenhuijzen GAP, et al. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg. 2014;101:1280–1289. 18. Van Der Meij W, Rombouts AJM, Rutten H, et al. Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients: A Review. Dis Colon Rectum. 2016;59:148–156. 19. Lee DJK, Sagar PM, Sadadcharam G, et al. Advances in surgical management for locally recurrent rectal cancer: How far have we come? World J Gastroenterol. 2017;23:4170–4180. 20. Calvo FA, Sole C V., Rutten HJ, et al. ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in locally recurrent rectal cancer. Clin Transl Radiat Oncol. 2020;24:41–48. 21. Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMAOncol.;4 . Epub aheadof print 2018. DOI: 10.1001/jamaoncol.2018.0071. 22. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before totalmesorectal excision (TME) versus preoperative chemoradiotherapy, TME, andoptional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. 23. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCERPRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–715.
RkJQdWJsaXNoZXIy MTk4NDMw